Greg Mayes (Engage)
Months after steering a seizure rescue therapy to market, UCB bags another promising late-stage asset for $125M upfront
UCB has picked up an epilepsy drug-device from a buyout that will cost at most $270 million, tucking a Phase III-ready project and the team …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
